The bacteria Fusobacterium nucleatum is prevalent in periodontal disease (gum disease), but also in some chronic diseases and cancers, such as colorectal cancer. The bacteria F. nucleatum is normally found in the mouth (oral) microbiome, and its numbers increase as periodontal disease inflammation increases.
It is thought that sometimes the bacteria leaves the mouth and travels to other parts of the body, where it can promote cancer and other diseases.
A recent study found that the antibiotic FP 100 (Hygromycin A) totally eliminates the F. nucleatum bacteria in the mouth, and without causing harm to the mouth microbiome or gut microbiome. This is because it is a narrow spectrum antibiotic - only targets the harmful bacteria, and not all (both good and harmful) bacteria. While the study was only done in mice, this is promising and welcome news.
Eliminating the harmful bacteria in the mouth would potentially prevent some chronic diseases and cancers. Now we need further studies to see if this finding holds up in humans.
From Medical Xpress: First narrow-spectrum antibiotic successfully eliminates Fusobacterium nucleatum, a gum disease pathogen
In a study published in the Journal of Oral Microbiology, ADA Forsyth scientists found that FP 100 (Hygromycin A), a first-in-class, small molecule, narrow-spectrum antibiotic, successfully eradicates Fusobacterium nucleatum without harming the oral or gut microbiomes.
Fusobacterium is a key pathogen triggering the onset of periodontitis (gum disease), and its progression has been linked with many serious systemic diseases. The researchers' recent discovery could help in the fight against severe gum disease and related systemic conditions.
FP 100 as an effective treatment for periodontitis
"This type of black and white data almost never happens," said Alpdogan Kantarci, DDS, Ph.D., a senior scientist at ADA Forsyth who led the study. "The results were so clear. With FP 100, we can eliminate Fusobacterium nucleatum from the oral cavity, reverse tissue destruction and prevent disease progression without harming the beneficial microbiome."
Lead authors, Dr. Nil Yakar Yilmaz and Dr. Ozge Unlu on Dr. Kantarci's team, demonstrated the drug was effective both in vitro and in a mouse model of periodontal disease. Drs. Lujia Cen, Hatice Hasturk, Tsute Chen, Wenyuan Shi, and Xuesong He also contributed to this exciting research.
"The findings provide strong evidence that FP 100 could be a game-changer in the treatment of severe gum disease," said Matt Tindall, Co-Founder and Chief Executive Officer of Flightpath Biosciences, Inc. "This antibiotic could work to prevent or treat advanced gum disease."
Gum disease affects over 47% of individuals aged 30 and older, with the prevalence increasing to 60% in those aged 65 and older. The later stages of the disease are characterized by progressive destruction of jawbone tissue and can lead to tooth loss. Current treatments focus on slowing the progression of the disease, but most of these are not covered by dental insurance. There is no available cure.
One of the most exciting findings in this study is that the antibiotic is effective at targeting just Fusobacteria without harming beneficial bacteria necessary for maintaining human health. Periodontal disease has long been a challenge to treat effectively because antibiotics typically wipe out both harmful and beneficial bacteria.
Implications for systemic health
The potential impact of this antibiotic extends far beyond the mouth, potentially preventing the development of serious chronic diseases, including heart disease, colon and pancreatic cancers, Alzheimer's disease, preterm birth, inflammatory bowel disease, and rheumatoid arthritis.
"Fusobacterium is an insidious pathogen," said Dr. Kantarci. "Studies show it can travel from the oral cavity to other places, where it colonizes and causes disease. We recently published a study showing that Fusobacterium can enter human cells like a Trojan horse and travel undetected to other parts of the body where they colonize and cause disease. Eliminating the bacteria early in the oral cavity is also systemic prevention."
This promising antibiotic candidate, FP 100 (hygromycin A), was rediscovered by a team of researchers led by Kim Lewis, Ph.D., Northeastern University, who focused on its ability to target the bacterium Borelliella burgdorferi, which causes Lyme disease.